SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported) October 23, 2002
----------------------------------------------------------------
Generex Biotechnology Corporation
---------------------------------
(Exact name of registrant as specified in its charter)
Delaware 000-25169 82-049021
----------------------------- ------------ ------------------
(State or other jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
33 Harbor Square, Suite 202, Toronto, Ontario Canada M5J 2G2
-------------------------------------------------------------------
(Address of principal executive offices) (Zip Code)
Registrant's telephone number, including area code 416/364-2551
---------------------------------------------------------------
-------------------------------------------------------------
(Former name or former address, if changed since last report)
Item 5. Other Events
Dr. Gerald Bernstein has been elected a director of Generex Biotechnology
Corporation.
Dr. Bernstein, M.D., F.A.C.P. graduated from Dartmouth College and Tufts
University School of Medicine. He is board certified in internal medicine (1966)
and endocrinology and metabolism (1973). Dr. Bernstein is an associate clinical
professor at the Albert Einstein College of Medicine in New York. He is an
attending physician at Beth Israel Medical Center, and physician emeritus at
Lenox Hill Hospital and Montefiore Medical Center, all in New York. He was
formerly Director of the Beth Israel Health Care Systems Diabetes Management
Program. Dr. Bernstein was president of the American Diabetes Association in
1998-99 and was for many years a member of the ADA's Board of Directors and its
Executive Committee. He received the ADA's Banting Medal for Service in 1999.
Dr. Bernstein presently serves on several ADA committees and on the Board of
Directors of the American Diabetes Association Research Foundation.
Dr. Bernstein has an employment agreement with Generex in connection with his
service as Vice President of Medical Affairs of Generex, a position he accepted
in October of 2001. Dr. Bernstein will continue to serve as Vice President of
Medical Affairs under the current terms of his employment agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
GENEREX BIOTECHNOLOGY CORPORATION
Dated: October 29, 2002 By: /s/ E. Mark Perri
-------------------------------------
E. Mark Perri, Chairman and CFO